Our mRNAi GOLD™ Pipeline Targets

We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases.

Disease
Target
Discovery
Preclinical
Phase I
Ph II
Ph III
Proprietary/Partnered
clinical Clinical
SLN360
Cardiovascular disease with high Lp(a)
Lp(a)
Silence Logo
SLN124
Beta Thalassemia
Myelodysplastic Syndrome
Polycythemia Vera (PV)
TMPRSS6
Silence Logo
Multiple programs
Undisclosed
Undisclosed
Silence Logo
SLN-HAN-1
Undisclosed
Undisclosed
Silence Logo*
SLN501
SLN-MNK-2
SLN-MNK-3
Complement-mediated diseases
C3
Undisclosed
Undisclosed
mallinckrodt Logo
SLN-AZ-1
SLN-AZ-2
Undisclosed
Undisclosed
Undisclosed
Undisclosed
astrazeneca Logo

* Silence retains exclusive rights to this program outside of the China region, including Hong Kong, Macau and Taiwan